Anti-Opioid Peptides

John Q. Wang,Eugene E. Fibuch,Shinobu Sakurada,Ji-Sheng Han

DOI: https://doi.org/10.1016/b978-012369442-3/50190-2

2006-01-01

Abstract:The first demonstration in 1979 of an anti-opioid peptide and prediction of the existence of other endogenous anti-opioid peptides in the central nervous system (CNS) has prompted extensive research endeavors exploring and identifying these peptides during the past two and a half decades. Several peptides that fall into this category include cholecyctokinin (CCK), neuropeptide FF (NPFF), angiotensin II, Tyr-MIF-1 (Tyr-Pro-Leu-Gly-NH2)-related peptides, and more recently nociceptin (orphanin FQ). Hypothetically, they are collectively viewed as a negative feedback system to antagonize the excessive activation of the opioid receptors induced by the repeated administration of opiates or excessive release of opioid peptides. From a practical point of view, the blockade of the anti-opioid peptides may have clinical implications for the treatment of intractable pain.